Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

BACKGROUND: The BNT162b2 mRNA (Pfizer–BioNTech) and ChAdOx1 nCoV-19 (Oxford–AstraZeneca) COVID-19 vaccines have shown high efficacy against disease in phase 3 clinical trials and are now being used in national vaccination programmes in the UK and several other countries. Studying the real-world effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasileiou, Eleftheria, Simpson, Colin R, Shi, Ting, Kerr, Steven, Agrawal, Utkarsh, Akbari, Ashley, Bedston, Stuart, Beggs, Jillian, Bradley, Declan, Chuter, Antony, de Lusignan, Simon, Docherty, Annemarie B, Ford, David, Hobbs, FD Richard, Joy, Mark, Katikireddi, Srinivasa Vittal, Marple, James, McCowan, Colin, McGagh, Dylan, McMenamin, Jim, Moore, Emily, Murray, Josephine LK, Pan, Jiafeng, Ritchie, Lewis, Shah, Syed Ahmar, Stock, Sarah, Torabi, Fatemeh, Tsang, Ruby SM, Wood, Rachael, Woolhouse, Mark, Robertson, Chris, Sheikh, Aziz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064669/
https://www.ncbi.nlm.nih.gov/pubmed/33901420
http://dx.doi.org/10.1016/S0140-6736(21)00677-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064669/
https://www.ncbi.nlm.nih.gov/pubmed/33901420
http://dx.doi.org/10.1016/S0140-6736(21)00677-2

Ejemplares similares